Abstracts tagged "autoimmune diseases"

Abstract Number: PP09 • 2018 ACR/ARHP Annual Meeting
Improved Quality of Life and Decreased Symptoms of Lupus with Diet, Exercise, and Functional Medicine
Marisa Zeppieri-Caruana, Lupus Chick, New York, NY
Background/Diagnosis: Like most people who live with a chronic illness and/or autoimmune disease, my story started long before I realized. Symptoms came and went throughout…
Abstract Number: PP10 • 2018 ACR/ARHP Annual Meeting
Using a Mobile App to Facilitate Patient-Doctor Discussions to Make Informed Decisions Regarding ‘Painsomnia’
Shelley Fritz¹, Kristine Carandang² and Dawn Gibson³, ¹ArthritisPower Patient Partner: CreakyJoints/Global Healthy Living Foundation, Tampa, FL, ²Chan Division of Occupational Science & Occupational Therapy, University of Southern California, Los Angeles, CA, ³Founder #SpoonieChat; CreakyJoints/Global Healthy Living Foundation Patient Partner, Upper Nyack, NY
Background/Diagnosis: As a patient with AS, Dawn founded #SpoonieChat to provide a space on twitter for people living with chronic diseases to support each other.…
Abstract Number: 9 • 2018 ACR/ARHP Annual Meeting
Integration of Cytokine Profiles with Distinct B-Cell Functions Reveals a Specific Micro-Environmental Framework in Autoimmune Diseases
Quentin Simon¹, Alexis Grasseau², Bénédicte Rouvière², Laetitia Le Pottier², Divi Cornec³, Maria Orietta Borghi⁴, Rocio Aguilar Quesada⁵, Yves Renaudineau^2,6, Marta Alarcón-Riquelme⁷, Jacques-Olivier Pers¹ and Sophie Hillion^2,6, ¹U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ²U1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, Brest, France, ³Hopital La Cavale Blanche, Brest, France, ⁴University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁵Biobanco Del Sistema Sanitario Publico de Andalucía, Sevilla, Spain, ⁶CHU de Brest, Brest, France, ⁷Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: The functional duality of B cells is central to balance immune homeostasis by regulating or promoting the immune response. However, the mechanisms by which…
Abstract Number: 126 • 2018 ACR/ARHP Annual Meeting
Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki¹, Satoshi Ebata¹, Kouki Nakamura¹, Yoshihide Asano¹, Yutaka Kazoe², Kazuma Mawatari², Takehiko Kitamori² and Shinichi Sato¹, ¹Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disorder that is characterized by fibrosis and vascular damage in the skin and other visceral organs, with…
Abstract Number: 843 • 2018 ACR/ARHP Annual Meeting
Localization of the Voltage-Gated Sodium Channel 1.7 in Peripheral Monocytes Contributes to Activation of BAFF Signaling in Monocytes of Patients with Primary Sjögren’s Syndrome
Keiko Yoshimoto, Yumi Ikeda, Katsuya Suzuki and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: In our previous study, we have reported that IL-6 production was robustly increased in BAFF-stimulated peripheral monocytes of patients with primary Sjögren’s syndrome (pSS)…
Abstract Number: 1182 • 2018 ACR/ARHP Annual Meeting
The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases
Wen-Nan Huang¹, Yi-Ming Chen¹, Wei-Ting Hung², Yu-Wan Liao³ and Yi-Hsing Chen¹, ¹Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ³Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Patients with autoimmune diseases are associated with an increased risk of osteoporotic fracture. Anti-osteoporotic treatment could diminish re-fracture rates in post-menopause women. However, treatment…
Abstract Number: 1584 • 2018 ACR/ARHP Annual Meeting
Evaluation of the Performance of the 2016 American College of Rheumatology-European League Against Rheumatism (Acr-Eular) Classification Criteria for Primary Sjogren`S Syndrome in Different Centers of Argentina
Hugo Najera¹, Marta Mamani², Anastasia Secco¹, Fernando Melo³, Cristian Troitiño⁴, Felix Romanini Sr.², Emmanuel Guerra², Antonio Catalan Pellet⁵, Silvia Beatriz Papasidero⁶, Rodrigo Aguila Maldonado⁷, Mercedes Garcia⁷, Mariano Rivero⁸, Juan Carlos Barreira⁹, ivan remolina¹⁰, A. perdomo¹¹, quevedo mayorga¹⁰, M.J. santacruz¹² and j demarchi¹⁰, ¹Rheumatology Section, Hospital Bernardino Rivadavia, CABA, Argentina, ²Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ³Rheumatology Department, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁴Reumatologia, Hospital Bernardino Rivadavia, CAPITAL FEDERAL, Argentina, ⁵Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁶Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ⁷Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ⁸Rheumatology, Consultorios Externos Vacarezza,Alberdi,Pcia Buenos Aires, Pcia Buenos Aires, Argentina, ⁹Rheumatology Unit, Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ¹⁰hospital britanico, Buenos Aires, Argentina, ¹¹hospital nuestra señora de la merced, alberti, Argentina, ¹²hospital tornu, Buenos Aires, Argentina
Background/Purpose: Primary Sjögren`s Syndrome (pSS) is a multisystemic, autoimmunity disease, characterized mainly by the hypofunction of the salivary and lacrimal glands, however the clinical spectrum…
Abstract Number: 1771 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival of Renal Transplantation in Rapidly Progressive Glomerulonephritis (RPGN). Study of 43 Cases from a Single Center
Belén Atienza-Mateo¹, Lara Sánchez-Bilbao¹, José Luis Martín-Varillas¹, Marina de Cos-Gómez², Íñigo González-Mazón¹, Diana Prieto Peña³, Monica Calderón Goercke³, Emilio Rodrigo Calabia², Juan Carlos Ruiz San Millán², Miguel Angel González-Gay¹ and Ricardo Blanco⁴, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain
Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized histology by presence of crescents and clinically by rapid and severe decline in kidney function. Thus, it may…
Abstract Number: 1002 • 2017 ACR/ARHP Annual Meeting
Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)
Torhild Garen¹, Karoline Lerang¹, Anna Maria Hoffmann-Vold², Helena Andersson¹, Øyvind Midtvedt¹, Karin Kilian¹, Ragnar Gunnarsson¹, Birgir Gudbrandsson¹, Gudrun Norby¹, Oyvind Molberg² and Øyvind Palm¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Survival is decreased in patients with connective tissue diseases (CTDs) and vasculitis, however few studies have compared the mortality between the specific diseases prospectively…
Abstract Number: 2121 • 2017 ACR/ARHP Annual Meeting
Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies
Danielle Baldo¹, Alessandra Dellavance¹, Maria Lucia Ferraz² and Luis Eduardo C. Andrade^3,4, ¹Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ²Gastroenterology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Immunology Division, Fleury Medicine and Health, São Paulo, Brazil
Background/Purpose: Circulating autoantibodies precede clinical onset of several autoimmune diseases. The characteristics of the so-called pre-clinical stage of autoimmune diseases are poorly understood. Anti-mitochondria autoantibodies…
Abstract Number: 1023 • 2017 ACR/ARHP Annual Meeting
The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)
Chaim Putterman¹, Armando Gabrielli², Alexandra Balbir-Gurman³, Pennina Safer⁴, Keren Jakobi-Brook⁴, Rachel Sorek⁴, Ilana Gluzman⁴, Steve Wallace⁵ and Irun R. Cohen^4,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Istituto di Clinica Medica dell'Università di Ancona, Ancona, Italy, Ancona, Italy, ³Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel, Haifa, Israel, ⁴ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁵ImmunArray Inc., VA, USA, Richmond, VA, ⁶Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to…
Abstract Number: 2128 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer
Noha Abdel-Wahab^1,2, Mohsin Shah¹, Maria A. Lopez-Olivo¹ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: The incidence and management of rheumatologic immune-related adverse events (irAEs) as a consequence of the checkpoint inhibitor (CPI) therapy in patients with cancer has…
Abstract Number: 1064 • 2017 ACR/ARHP Annual Meeting
Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases
Hitoshi Hasegawa¹, Takuya Matsumoto¹, Endy Adnan², Jun Ishizaki¹, Koichiro Suemori¹ and Masaki Yasukawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan
Background/Purpose: Tolerogenic dendritic cells (tDCs) are a promising therapeutic tool for specific induction of immunological tolerance. Human tDCs can be generated ex vivo using various…
Abstract Number: 2142 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis
Richard Yeker¹, Iago Pinal-Fernandez², Takayuki Kishi³, Ira N. Targoff⁴, Frederick W Miller³, Lisa G Rider³ and Andrew Mammen⁵, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD
Background/Purpose: Autoantibodies recognizing cytosolic 5’-nucleotidase 1A (NT5C1A) are present in the sera of adults with myositis and other autoimmune diseases. They are especially prevalent in…
Abstract Number: 1068 • 2017 ACR/ARHP Annual Meeting
Impact of TNF Antagonist Treatment on the Gut Microbiome In Vivo
Odile Gabay¹, Jonathan Vicenty², Grant Wunderlin³, Linda Tiffany², Wells Wu⁴, Vahan Simonyan⁵ and Kathleen A Clouse⁶, ¹Office of Biotechnology Products /Center for Drug Evaluation and Research DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, ²Office of Biotechnology Products, Center for Drug Evaluation and Research, DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, ³Center for Drug Evaluation and Research CDER DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, ⁴Center for Biologic Evaluation and Research OMPT, U.S. Food and Drug Administration, Silver Spring, MD, ⁵Center for Biologic Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, ⁶Office of Biotechnology Products /Center for Drug Evaluation and Research,DBRRI, U.S. Food and Drug Administration, Silver Spring, MD
Background/Purpose: Auto-immune diseases are in constant progression in the US. Biologic therapeutics have been used successfully to treat these diseases, but have presented some unique…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].